US Patent

US8168616 — Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension

Formulation · Assigned to Novartis AG · Expires 2026-07-03 · 0y remaining

Vulnerability score 65/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a combination of a renin inhibitor and an angiotensin receptor inhibitor for treating hypertension.

USPTO Abstract

The invention relates to a combination comprising the renin inhibitor of formula (I) or a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

Patent Metadata

Patent number: US8168616
Jurisdiction: US
Classification: Formulation
Expires: 2026-07-03
Drug substance claim: No
Drug product claim: Yes
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.